Skip to content

Author: API User

SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

By API User

Partnership with CHC in Taiwan will pilot SoluPet’s flagship Neuronal Defense™ formulation through CHC’s veterinary and consumer-health ecosystem TORONTO–BUSINESS WIRE– SoluPet,the data and science-driven pet cognitive health company developing advanced cognitive-aging support for senior dogs, today announced a strategic partnership with CHC, one of Asia’s largest publicly traded healthcare organizations. CHC – with more than … Continued

Boomi Named a 2025 Geo and Global AWS Partner Award Finalist

By API User

Boomi recognized as Rising Star Partner of the Year (Technology) finalist that helps customers drive innovation CONSHOHOCKEN, Pa.–BUSINESS WIRE– Boomi™, the leader in AI-driven automation, today announced it is a finalist for a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive … Continued

PHOTRON LIMITED Announces Acquisition of AOS Technologies AG

By API User

~ Accelerating Expansion of High-Speed Camera Business ~ TOKYO–BUSINESS WIRE– PHOTRON LIMITED, a global leader in high-speed and scientific imaging solutions, today announced its acquisition of AOS Technologies AG, a Swiss-based designer and manufacturer of advanced high-speed imaging systems serving automotive, aerospace, industrial, and defense markets. Founded in 2002, AOS Technologies has earned worldwide recognition … Continued

Pink Changing Lives®: Mary Kay Builds 11th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings

By API User

Each year, Mary Kay supports causes that enrich millions of women’s lives globally, including access to education DALLAS–BUSINESS WIRE– Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic … Continued

AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies

By API User

Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212 (212Pb) The established capability to receive and process high-activity 228Th, provides a key competitive advantage in scaling up 212Pb production to support the rapid advancement of 212Pb-ADVC001 (ADVC001) clinical development and the expanding pipeline The received 228Th will be processed … Continued

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

By API User

Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL Additional ASH data from investigational BTK degrader, BGB-16673, highlight potential first- and best-in-class activity with durable responses in heavily pretreated patients with CLL SAN CARLOS, Calif.–BUSINESS WIRE– BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a … Continued

Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy

By API User

RICHARDSON, Texas, Dec. 08, 2025 (GLOBE NEWSWIRE) — Mavenir, the software company building AI-by-design mobile networks, today announced a strong leadership team to accelerate its vision for telco-first, cloud-native, AI-by-design networks. This transformation follows the company’s recent recapitalization and aligns with a refreshed product strategy focused on mobile core, AI-enabled automation, and cloud-native platforms. New … Continued

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

By API User

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, … Continued

Coeur Provides Palmarejo Exploration Update

By API User

2025 drilling further extends near-mine resources, returns multi-kilo silver grades at San Miguel and discovers new mineralization at East Palmarejo CHICAGO–BUSINESS WIRE– Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today provided an update on the 2025 exploration program at its Palmarejo gold-silver complex located in southwest Chihuahua, Mexico, which marks its largest exploration … Continued